Similarly, durable response to combined EGFR-TKI and Crizotinib for concurrent EGFRm+ and de novo MET amplification was also observed in patients with sarcomatoid phenotype of NSCLC [90] and in a patient with two primary pulmonary adenocarcinomas, one harboring an EGFR ex19del and the other a MET amplification [91]. The gene discussed is MET; the disease is non-small cell lung carcinoma.